[Effects of 4-hour erect posture and furosemide on the blood level of atrial natriuretic peptide in patients with primary arterial hypertension]. 1990

M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
Kliniki Nadciśnienia Tetniczego i Chorób Naczyń, AM w Warszawie Kierownik.

The arterial pressure, the pulse frequency, the concentration of arterial natriuretic peptide (ANP), the aldosterone++ concentration and the plasma renin activity were determined in patients with primary hypertension after administration of furosemide in conditions of active assuming of erect position. The ANP concentration was lowered in that conditions both in the patients and in healthy subjects.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009320 Atrial Natriuretic Factor A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. ANF,ANP,Atrial Natriuretic Peptide,Atrial Natriuretic Peptides,Atriopeptins,Auriculin,Natriuretic Peptides, Atrial,ANF (1-126),ANF (1-28),ANF (99-126),ANF Precursors,ANP (1-126),ANP (1-28),ANP Prohormone (99-126),ANP-(99-126),Atrial Natriuretic Factor (1-126),Atrial Natriuretic Factor (1-28),Atrial Natriuretic Factor (99-126),Atrial Natriuretic Factor Precursors,Atrial Natriuretic Factor Prohormone,Atrial Natriuretic Peptide (1-126),Atrial Pronatriodilatin,Atriopeptigen,Atriopeptin (1-28),Atriopeptin (99-126),Atriopeptin 126,Atriopeptin Prohormone (1-126),Cardiodilatin (99-126),Cardiodilatin Precursor,Cardionatrin I,Cardionatrin IV,Prepro-ANP,Prepro-CDD-ANF,Prepro-Cardiodilatin-Atrial Natriuretic Factor,Pro-ANF,ProANF,Proatrial Natriuretic Factor,Pronatriodilatin,alpha ANP,alpha-ANP Dimer,alpha-Atrial Natriuretic Peptide,beta-ANP,beta-Atrial Natriuretic Peptide,gamma ANP (99-126),gamma-Atrial Natriuretic Peptide,Natriuretic Peptide, Atrial,Peptide, Atrial Natriuretic,Peptides, Atrial Natriuretic,Prepro ANP,Prepro CDD ANF,Prepro Cardiodilatin Atrial Natriuretic Factor,Pro ANF,alpha ANP Dimer,alpha Atrial Natriuretic Peptide,beta ANP,beta Atrial Natriuretic Peptide,gamma Atrial Natriuretic Peptide
D011187 Posture The position or physical attitude of the body. Postures
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D003864 Depression, Chemical The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Depression,Chemical Depressions,Depressions, Chemical
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1989, Polski tygodnik lekarski (Warsaw, Poland : 1960),
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1987, Kardiologia polska,
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1985, Lancet (London, England),
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1991, Clinical and experimental hypertension. Part A, Theory and practice,
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1992, Problemy endokrinologii,
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1988, Polskie Archiwum Medycyny Wewnetrznej,
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
September 1990, The European respiratory journal,
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
July 1988, Kidney international,
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
April 2022, Hypertension (Dallas, Tex. : 1979),
M Lapiński, and K Stepniakowski, and H Ignatowska-Switalska, and B Wocial, and A Januszewicz, and J Chodakowska, and H Chlebus, and W Januszewicz
January 1994, Klinicheskaia meditsina,
Copied contents to your clipboard!